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Sphingosine 1-phosphate receptor-1 (S1P1), a novel therapeutic target for multiple sclerosis, regulates
lymphocyte trafficking, heart rate, and vascular function. The discovery of NIBR-0213, a competitive antag-
onist for S1P1 that inhibits autoimmune inflammation while sparing bradycardia (Quancard et al., in this issue
of Chemistry & Biology), suggests that fine-tuning of S1P1 modulators may lead to novel immunemodulators
with better efficacy to adverse events ratio.Sphingosine 1-phosphate (S1P) is
a plasma-borne lipid mediator that binds
with high affinity to five cell-surface G
protein-coupled receptors (S1P1–5) and
regulates a wide variety of biological
responses (Obinata and Hla, 2012).
Mammalian plasma contains abundant
S1P bound to ApoM on HDL particles
and serum albumin (Christoffersen et al.,
2011). The role of S1P in lymphocyte traf-
ficking was uncovered while studying the
immunomodulatory compound FTY720.
Specifically, S1P1 function on lympho-
cytes is necessary for the efficient egress
from secondary lymphoid organs into
lymph. It turns out that FTY720, a sphingo-
lipid mimetic, is phosphorylated into
FTY720-P, binds to S1P receptors, acti-
vates them acutely, but downregulates
S1P1 irreversibly (Cyster and Schwab,
2012). Thus, FTY720 administration leads
to rapid and reversible lymphopenia,
a property that was used as amechanistic
basis to treat autoimmune conditions.
FTY720 was highly efficacious in the
experimental autoimmune encephalomy-
elitis (EAE) model in mice and performed
well in clinical studies in the treatment of
multiple sclerosis (MS) (Brinkmann et al.,
2010), which led to its approval in manycountries as the first oral therapy for this
disease. The role of S1P as an important
regulator of immune cell trafficking has
now been established, and our knowl-
edge of beneficial and adverse effects of
S1P receptor modulators has increased.
Indeed, several selective agonists and
antagonists for S1P1 have been devel-
oped and tested for their efficacy in
various inflammatory disease models,
including the agonists AUY954, CYM-
5442, ONO-4641, Ponesimod, and
SEW2871 and the antagonists EXEL-
4541, TASP0277308, VPC44116, and
W146. However, some critical issues on
the mechanism of action of this class of
therapeutics remain outstanding. Given
that much effort has been expended in
the search for better S1P receptor-based
therapeutics, it is critical to better under-
stand the mechanism of S1P action and
how different modulators interfere with
the receptors.
The currently accepted mechanism of
action of FTY720 in the control of autoim-
mune inflammation focuses on modula-
tion of S1P1 function and alteration of
lymphocyte trafficking. Even though
FTY720-P is a strong agonist on four
S1P receptors, it potently induces irre-versible downregulation of S1P1 leading
to ubiquitinylation and proteosomal deg-
radation (Oo et al., 2007). As such, it
acts as a functional antagonist. Studies
using internalization-deficient knock-in
mice have suggested that S1P1 cell
surface residency on lymphocytes deter-
mine egress rates (Thangada et al.,
2010). In other words, the more S1P1 is
on the cell surface of lymphocytes, the
higher the probability of egress into
lymph. Indeed, MS patients on FTY720
show reduced numbers of CCR7+ central
memory T cells in peripheral blood (Brink-
mann et al., 2010), suggesting that inhibi-
tion of autoreactive T cell trafficking in MS
is involved in the therapeutic efficacy of
FTY720. However, an alternative model
was proposed by Rosen et al. (2008),
who argued that agonistic action of
FTY720-P on endothelial S1P1 receptors
allow the closure of egress portals and
thus inhibit lymphocyte trafficking. Given
that endothelial S1P1 receptor regulates
cell-cell and cell-matrix junctions and
control vascular permeability, this model
suggests that S1P1 agonists would have
potent effects on lymphocyte trafficking.
Indeed, a few of the first-generation
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Figure 1. Signaling Systems for Natural Ligand, Functional Antagonist, and Competitive Antagonist
(A) S1P activates S1P1 and regulates vascular permeability in endothelial cells and lymphocyte egress from secondary lymphoid organs. S1P1 is recycled back to
the cell surface after S1P-induced internalization.
(B) FTY720-P induces ubiquitin-dependent degradation of S1P1, resulting in functional antagonism, which induces increased vascular permeability and lympho-
penia. The agonistic effects of FTY720-P on S1P1, on the other hand, activate the GIRK channel on cardiomyocytes, leading to bradycardia.
(C) NIBR-0213 competitively antagonizes S1P1, which also induces increased vascular permeability and lymphopenia while sparing bradycardia.
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not induce appreciable lymphopenia,
which supported the endothelial egress
portal closure model by default. Although
the mechanism of action of S1P1 receptor
modulators is of considerable academic
interest, it is also important from a
therapeutic point of view, since the first
model predicts that the antagonism of
S1P1 is critical, whereas the second
model predicts that agonists would be
efficacious.
In this issue of Chemistry & Biology,
Quancard et al. (2012) report the
synthesis and characterization of a novel
S1P1 competitive antagonist, NIBR-
0213. It is potent and selective against
S1P1 and possesses desirable pharma-
cokinetic properties with high oral
bioavailability and slow clearance in
animal models. Interestingly, NIBR-0213
induced dose-dependent lymphopenia
in mice after oral administration, suggest-
ing that strong antagonism of lymphocyte
S1P1 receptor is sufficient to inhibit
lymphocyte egress. Importantly, NIBR-
0213 suppressed autoimmune inflamma-
tion in the EAE model in mice. CNS
inflammation and axonal degeneration
were significantly suppressed by NIBR-
0213 at 30-60 mg/kg, an extent compa-
rable to that achieved by FTY720 at
3 mg/kg. One of the adverse effects of
FTY720 in MS therapeutics is brady-
cardia, which is associated with the
agonistic effects of FTY720 on S1P1-dependent activation of G protein-
coupled inwardly rectifying potassium
(GIRK) channel in cardiomyocytes (Koyr-
akh et al., 2005). In contrast, because
NIBR-0213 lacks an agonistic activity on
S1P1, GIRK activation by NIBR-0213
was not observed in cardiomyocytes,
suggesting that NIBR-0213 and related
S1P1 antagonists will likely not induce
bradycardia. These data are exciting and
demonstrate that potent antagonism of
lymphocyte S1P1 is sufficient to achieve
immunomodulation while reducing brady-
cardic effects. However, NIBR-0213
induced increased pulmonary vascular
leakage at 6 hr posttreatment, similar to
other S1P1 antagonists (Rosen et al.,
2008), whereas it did not cause clinically
apparent pulmonary pathology after
chronic administration in the EAE model.
It is thought that impairment of endothelial
barrier function by S1P1 receptor modula-
tors is responsible for other adverse
events such as macular edema. Slight
depression of pulmonary function was
also seen in patients taking FTY720,
even though data from a phase III trial
did not indicate clinically relevant pulmo-
nary pathology (Brinkmann et al., 2010).
A head-to-head comparison of NIBR-
0213 and FTY720 in the induction of
pulmonary vascular permeability and
function in various animal models should
be performed to see if there is concern
in this class of compounds for vascular-
related adverse effects.Chemistry & Biology 19, September 21, 2012 ªAn important principle from the paper
by Quancard et al. (2012) is that it is
possible to learn about complex biolog-
ical signaling systems through systematic
analysis and the use of pharmacological
tools (Figure 1). Thus, a competitive
antagonist of S1P1 would likely possess
less cardiac adverse events while
achieving immunomodulatory effects.
The issue of vascular adverse effects not
withstanding, this study suggests that
further pursuit of S1P1 antagonists in
various immune disorders may well be
worthwhile. An optimistic view would
suggest that due to the differential regula-
tory mechanisms of surface S1P1 locali-
zation by CD69 and abundance of plasma
S1P, lymphocyte S1P1 receptors could
be more readily blocked than vascular
S1P1 by competitive antagonists.
However, this hypothesis will need to be
tested rigorously in preclinical models as
well as clinical trials. Nevertheless, recent
advances in S1P-based therapeutics will
undoubtedly increase our armamen-
tarium of anti-autoimmune strategies.ACKNOWLEDGMENTS
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Reactivating apoptosis is a major goal of cancer research, and MCL-1 has emerged as a primary pharmaco-
logical target. A screen for small molecules that could compete with stabilized helical peptides for MCL-1
binding yielded small molecule MIM1 (see the article by Cohen et al. in this issue of Chemistry & Biology).
MIM1 selectively targets MCL-1, and can kill MCL-1-dependent leukemia cells.Cancer is caused by an accumulation of
mutations in key pathways, resulting in
the acquisition of specific growth charac-
teristics that result inmalignancy (Hanahan
and Weinberg, 2011). One of these is
subversion of apoptosis, the cell’s pro-
grammed death pathway. Apoptosis
signaling senses severe DNA damage
and other insults and induces cell suicide,
limiting genomic instability and preventing
malignancy. Thus, reestablishing apo-
ptosis has emerged as a key therapeutic
strategy for combating a variety of solid
tumors and leukemias(Lessene et al.,
2008). Despite its promise, this approach
is a difficult one for traditional medicinal
chemistry because several of the key
signaling events are protein-protein inter-
actions, such as those among pro-
apoptotic and anti-apoptotic proteins in
the BCL-2 family (Verdine and Walensky,
2007). New approaches to targeting these
difficult interactions have generated potent
inhibitors of BCL-2 proteins, and many of
these inhibitors are being developed as
therapies. Two notable examples of thesenew approaches are fragment-based
drug design, which yielded the small
molecule ABT-737 and its analogs (Olters-
dorf et al., 2005; Tseet al., 2008), and ‘‘helix
stapling,’’ which yieldedmodified peptides
called SAHBs (stabilized a helices of Bcl-2
domains) (Stewart et al., 2010; Walensky
et al., 2004). In this issue of Chemistry &
Biology, Cohen et al. (2012) use a SAHB
in a high-throughput screen to find small
molecules that displace the SAHB from its
binding partner. In doing so, they suggest
that straightforward screening efforts may
benefit from the application of compounds
developed using more non-traditional
approaches.
The peptide used in the study is SAHBA,
which is a stapled analog of a helix from
the BCL-2 family protein MCL-1. Previous
work had shown that this modified
peptide binds MCL-1 with high affinity
and high selectivity over other BCL-2
family members (Stewart et al., 2010).
MCL-1 is an anti-apoptotic BCL-2 protein
whose overexpression drives diverse
cancers (Beroukhim et al., 2010). Inhibi-tors such ABT-737 and its analogs target
other BCL-2 family proteins but are not
effective against cells that overexpress
MCL-1. This indicates that inhibition of
both MCL-1 and BCL-2/BCL-XL may be
the best approach for reactivating
apoptosis (van Delft et al., 2006). In this
light, understanding MCL-1 specificity
and developing new classes of MCL-1
inhibitors are clear priorities for apoptosis
researchers.
The authors screened over 70,000
small molecules to find those that could
displace a fluorescently labeled SAHBA
from the BH3-binding domain of MCL-1.
These were further screened to identify
compounds that could not displace a
fluorescently labeled BAD-BH3 peptide
from the BH3-binding domain of BCL-
XL. Further screens checked the modes
of binding and the dose reponses of the
hits, and 28 compounds were carried
forward to liposome- and cell-based
assays that test functional activation of
apoptotic membrane permeabilization. Of
the compounds that performed well in
